For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...

chronic obstructive pulmonary disease (COPD), and patients who have received a lung transplant. It ... How a New Gut Microbe Drives the Gut-Lung Axis Dec. 19, 2024 — A team has discovered a new ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Therapies to treat IPF are limited ... and cellular interactions in distinct cell populations in chronic obstructive pulmonary disease ...

AerWave announced today that it completed the first-in-human feasibility study of its disease-modifying ultrasound lung ...

• Establish a supportive company culture. Business leaders can signal to employees that they should prioritize their ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.